688266 泽璟制药-U
已收盘 11-03 15:00:00
资讯
新帖
简况
泽璟制药（688266）2026年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 11-01 06:27
泽璟制药（688266）2026年三季报简析：营收净利润同比双双增长，盈利能力上升
“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？
澎湃新闻 · 10-29
“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？
泽璟制药（688266）10月28日主力资金净卖出1567.30万元
证券之星 · 10-29
泽璟制药（688266）10月28日主力资金净卖出1567.30万元
泽璟制药（688266）10月23日主力资金净卖出1137.05万元
证券之星 · 10-24
泽璟制药（688266）10月23日主力资金净卖出1137.05万元
泽璟制药：收到艾伯维1000万美元里程碑付款
格隆汇 · 10-20
泽璟制药：收到艾伯维1000万美元里程碑付款
大健康“A+H”退潮，谁还能上桌？
蓝鲸财经 · 10-15
大健康“A+H”退潮，谁还能上桌？
泽璟制药（688266）9月24日主力资金净卖出4392.41万元
证券之星 · 09-25
泽璟制药（688266）9月24日主力资金净卖出4392.41万元
每周股票复盘：泽璟制药（688266）新适应症上市申请获受理
证券之星 · 09-13
每周股票复盘：泽璟制药（688266）新适应症上市申请获受理
泽璟制药（688266）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月8日股价下跌0.9%
证券之星 · 09-08
泽璟制药（688266）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月8日股价下跌0.9%
泽璟制药（688266）披露注射用人促甲状腺素β新适应症上市申请获得受理，9月7日股价下跌0.7%
证券之星 · 09-07
泽璟制药（688266）披露注射用人促甲状腺素β新适应症上市申请获得受理，9月7日股价下跌0.7%
泽璟制药(688266.SH)：注射用人促甲状腺素β新适应症上市申请获得受理
智通财经 · 09-06
泽璟制药(688266.SH)：注射用人促甲状腺素β新适应症上市申请获得受理
每周股票复盘：泽璟制药（688266）重新递表港交所
证券之星 · 08-16
每周股票复盘：泽璟制药（688266）重新递表港交所
泽璟制药（688266）披露重新向香港联交所递交H股发行上市申请并刊发申请资料的公告，8月13日股价上涨0.27%
证券之星 · 08-13
泽璟制药（688266）披露重新向香港联交所递交H股发行上市申请并刊发申请资料的公告，8月13日股价上涨0.27%
新股消息 | 泽璟制药(688266.SH)再度递表港交所
智通财经 · 08-13
新股消息 | 泽璟制药(688266.SH)再度递表港交所
每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元
证券之星 · 08-09
每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元
泽璟制药（688266）2026年中报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 08-02
泽璟制药（688266）2026年中报简析：营收净利润同比双双增长，盈利能力上升
泽璟制药(688266)6月30日股东户数1.37万户，较上期增加64.17%
证券之星 · 08-01
泽璟制药(688266)6月30日股东户数1.37万户，较上期增加64.17%
泽璟制药(688266.SH)发布半年度业绩，归母净利润6.4亿元，同比扭亏为盈
智通财经 · 07-31
泽璟制药(688266.SH)发布半年度业绩，归母净利润6.4亿元，同比扭亏为盈
富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股
智通财经 · 07-21
富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股
泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%
证券之星 · 07-03
泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%
加载更多
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药-U","latestPrice":83.58,"timestamp":1793689200000,"preClose":85.15,"halted":0,"volume":3854876,"delay":0,"changeRate":-0.0184,"floatShares":265000000,"shares":265000000,"eps":2.1486,"marketStatus":"已收盘","change":-1.57,"latestTime":"11-03 15:00:00","open":84.25,"high":84.78,"low":81.92,"amount":320000000,"amplitude":0.0336,"askPrice":83.58,"askSize":25,"bidPrice":83.54,"bidSize":2,"shortable":0,"etf":0,"ttmEps":2.1486,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793755800000},"marketStatusCode":5,"adr":0,"adjPreClose":85.15,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793669400000,1793676600000],[1793682000000,1793689200000]],"highLimit":93.67,"lowLimit":76.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":12.87,"roa":"--","peRate":38.899749,"roe":"45.6%","epsLYR":-0.62,"committee":-0.752577,"marketValue":22124000000,"turnoverRate":0.0146,"status":1,"afterMarket":{"amount":50148,"volume":600,"close":83.58,"buyVolume":100,"sellVolume":0,"time":1793691237746,"indexStatus":"已收盘 11-03 15:30:00","preClose":85.15},"floatMarketCap":22124000000},"requestUrl":"/m/hq/s/688266","defaultTab":"news","newsList":[{"id":"2680427230","title":"泽璟制药（688266）2026年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2680427230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680427230?lang=zh_cn&edition=full","pubTime":"2026-11-01 06:27","pubTimestamp":1793485648,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泽璟制药发布2026年三季报。截至本报告期末，公司营业总收入15.36亿元，同比上升158.91%，归母净利润6.38亿元，同比上升783.25%。本报告期泽璟制药盈利能力上升，毛利率同比增幅2.92%，净利率同比增幅357.87%。本文数据来源于泽璟制药2026年三季报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100001481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679285027","title":"“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？","url":"https://stock-news.laohu8.com/highlight/detail?id=2679285027","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679285027?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:00","pubTimestamp":1793282441,"startTime":"0","endTime":"0","summary":"“基金买手”三季度重仓路径曝光，哪些主动权益基金被大幅增持？","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610293914932760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610293914932760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU0455707207.USD","LU0456827905.SGD","LU1580142542.USD","LU0456846285.SGD","LU2097828631.EUR","BK0183","LU0039217434.USD","LU2148510915.USD","LU1655091616.SGD","BK1589","LU0405327494.USD","LU1831875114.USD","HK0000181112.HKD","LU1997244956.HKD","LU2097828805.USD","688266","LU0051755006.USD","601318","LU0326950275.SGD","LU2495084118.USD","LU2097828714.EUR","LU0502904849.HKD","LU2097828474.EUR","SG9999002463.SGD","HK0000181138.USD","KURE","LU1934453819.USD","LU1997245177.USD","LU2399975544.HKD","BK0187","LU0149534421.HKD","LU1794554557.SGD","LU1064131003.USD","LU2242644610.SGD","BK0028","BK0239","LU1720050803.USD","LU0607220059.USD","BK1161","BK0012","LU1064130708.USD","BK0070","LU0244354667.USD","IE0005HP3H50.USD","LU0463099449.HKD","LU2213484517.USD","LU1188198961.HKD","01801","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679344602","title":"泽璟制药（688266）10月28日主力资金净卖出1567.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679344602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679344602?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:46","pubTimestamp":1793234808,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月28日收盘，泽璟制药报收于89.99元，下跌4.27%，换手率2.31%，成交量6.13万手，成交额5.56亿元。近5日资金流向一览见下表：泽璟制药融资融券信息显示，融资方面，当日融资买入2399.24万元，融资偿还1412.79万元，融资净买入986.45万元。泽璟制药主营业务：化学新药及生物新药的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900015136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","01477","688266","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677195903","title":"泽璟制药（688266）10月23日主力资金净卖出1137.05万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677195903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677195903?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:22","pubTimestamp":1792801333,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，泽璟制药报收于103.75元，上涨4.27%，换手率1.11%，成交量2.93万手，成交额2.93亿元。近5日资金流向一览见下表：泽璟制药融资融券信息显示，融资方面，当日融资买入1206.04万元，融资偿还1904.99万元，融资净偿还698.95万元。泽璟制药主营业务：化学新药及生物新药的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","01477","688266","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676662982","title":"泽璟制药：收到艾伯维1000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2676662982","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676662982?lang=zh_cn&edition=full","pubTime":"2026-10-20 18:33","pubTimestamp":1792492417,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675619300","title":"大健康“A+H”退潮，谁还能上桌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2675619300","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675619300?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:16","pubTimestamp":1792055774,"startTime":"0","endTime":"0","summary":"2026年以来，A股大健康上市公司的赴港上市明显降温。可以说，港股终止上市也没有与该风波有直接关联。该企业负债率约25%，因此市场猜测“A+H”上市的诉求并非缺钱续命，而是全球化战略布局。头部医疗器械、创新药龙头持续坚守“A+H”双平台战略，持续获得机构认可，港股上市成为全球化发展的配套工具。归根结底，大健康板块的“A+H”上市潮退是行情、规则、企业基本面三重因素叠加的结果。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792043506360832246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1781817850.SGD","BK4588","LU2348774022.SGD","SGXZ49509284.SGD","BK0229","LU0594300419.USD","IE0008368742.USD","LU0823426480.USD","LU1979443071.USD","LU0572944931.SGD","LU1734074674.USD","LU0327786744.USD","LU0084288322.USD","LU1997245094.SGD","688266","688166","LU1655091616.SGD","LU0823426308.USD","IPOS","LU0359201612.USD","BK4585","KCAI","LU2148510915.USD","LU0594300179.USD","IE00B031J352.USD","IE00B031HY20.USD","LU0405327148.USD","IE00B29SXG58.USD","LU0650527681.SGD","LU1934453819.USD","LU2213484517.USD","LU2488822045.USD","VXUS","BK0251","IE0031814852.USD","LU2348773727.SGD","LU1064131003.USD","LU0359202008.SGD","300760","LU1064130708.USD","688506","IE0005HP3H50.USD","LU1820825898.SGD","LU1688375341.USD","688639","LU1146622755.USD","LU2424517915.HKD","SGXZ81163826.USD","LU0605514214.HKD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670199114","title":"泽璟制药（688266）9月24日主力资金净卖出4392.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670199114","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670199114?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:23","pubTimestamp":1790295836,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，泽璟制药报收于108.95元，下跌6.12%，换手率1.31%，成交量3.48万手，成交额3.86亿元。近5日资金流向一览见下表：泽璟制药融资融券信息显示，融资方面，当日融资买入2723.02万元，融资偿还2217.61万元，融资净买入505.42万元，连续3日净买入累计1691.62万元。泽璟制药主营业务：化学新药及生物新药的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1191","01477","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507992","title":"每周股票复盘：泽璟制药（688266）新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507992","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507992?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:09","pubTimestamp":1789236550,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，泽璟制药报收于106.67元，较上周的117.99元下跌9.59%。本周，泽璟制药9月7日盘中最高价报118.08元。本周关注点来自公司公告汇总：注射用人促甲状腺素β新适应症上市申请获国家药监局受理。公司公告汇总泽璟制药关于自愿披露注射用人促甲状腺素β新适应症上市申请获得受理的公告苏州泽璟生物制药股份有限公司收到国家药品监督管理局核准签发的《受理通知书》，公司递交的注射用人促甲状腺素β新适应症上市申请已获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK1191","BK1574","BK0239","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329073","title":"泽璟制药（688266）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月8日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329073","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665329073?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:57","pubTimestamp":1788861455,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，泽璟制药报收于116.11元，较前一交易日下跌0.9%，最新总市值为307.35亿元。泽璟制药于近日发布《关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》。公告显示，公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心网络互动方式，就公司2026年半年度经营成果、财务状况等与投资者进行交流。公司已于2026年8月1日披露2026年半年度报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1191","01477","BK1574","BK1161","BK0239","688266","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311096","title":"泽璟制药（688266）披露注射用人促甲状腺素β新适应症上市申请获得受理，9月7日股价下跌0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665311096?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:44","pubTimestamp":1788774298,"startTime":"0","endTime":"0","summary":"截至2026年9月7日收盘，泽璟制药报收于117.16元，较前一交易日下跌0.7%，最新总市值为310.13亿元。该股当日开盘117.99元，最高118.08元，最低114.6元，成交额达2.78亿元，换手率为0.9%。泽璟制药当日发布公告称，公司收到国家药品监督管理局核准签发的《受理通知书》，其递交的注射用人促甲状腺素β新适应症上市申请已获受理。上市申请尚需经过审评、现场检查和审批等环节，取得注册批件的时间和结果存在不确定性。该事项对公司近期业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1191","01477","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665361627","title":"泽璟制药(688266.SH)：注射用人促甲状腺素β新适应症上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665361627","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665361627?lang=zh_cn&edition=full","pubTime":"2026-09-06 15:36","pubTimestamp":1788680173,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《受理通知书》，公司递交的注射用人促甲状腺素β(曾用名：注射用重组人促甲状腺激素，商标：泽速宁®)新适应症上市申请获得受理，本次获得受理的适应症是用于无远处转移的分化型甲状腺癌患者甲状腺全切或近全切除术后协同放射性碘(131I)清除残余甲状腺组织的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0239","01477","688266","IPOS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659751801","title":"每周股票复盘：泽璟制药（688266）重新递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2659751801","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659751801?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:47","pubTimestamp":1786816031,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，泽璟制药报收于120.4元，较上周的121.7元下跌1.07%。本周，泽璟制药8月10日盘中最高价报127.74元。泽璟制药当前最新总市值318.71亿元，在化学制药板块市值排名12/149，在两市A股市值排名642/5207。本周关注点公司公告汇总：泽璟制药重新向香港联交所递交H股发行上市申请并刊发申请资料。本次发行尚需中国证监会、香港证监会及港交所等批准，存在不确定性。公司将及时履行信息披露义务，提醒投资者注意风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK1191","BK0239","688266","BK1574","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659016846","title":"泽璟制药（688266）披露重新向香港联交所递交H股发行上市申请并刊发申请资料的公告，8月13日股价上涨0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659016846","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659016846?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:18","pubTimestamp":1786630701,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，泽璟制药报收于120.22元，较前一交易日上涨0.27%，最新总市值为318.23亿元。近日，苏州泽璟生物制药股份有限公司披露《关于重新向香港联交所递交H股发行上市申请并刊发申请资料的公告》。公告显示，公司于2026年8月12日重新向香港联合交易所有限公司递交发行H股股票并在香港联交所主板上市的申请，并在港交所网站刊登了申请材料。本次发行尚需中国证监会、香港证监会及港交所等批准，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688266","BK1191","BK0239","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659863741","title":"新股消息 | 泽璟制药(688266.SH)再度递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2659863741","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659863741?lang=zh_cn&edition=full","pubTime":"2026-08-13 06:24","pubTimestamp":1786573458,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月12日披露，苏州泽璟生物制药股份有限公司向港交所主板递交上市申请，中金公司为独家保荐人。该公司曾于2025年12月19日递表港交所。招股书显示，泽璟制药是一家综合生物制药企业，专注于创新型小分子及生物制剂疗法的发现、研发及商业化，策略聚焦于肿瘤学、自身免疫性疾病、止血╱血液病领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","HEXmain","BK1574","688266","01477","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673625","title":"每周股票复盘：泽璟制药（688266）首次半年度盈利6.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673625","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673625?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:21","pubTimestamp":1786209669,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，泽璟制药报收于121.7元，较上周的122.1元下跌0.33%。本周，泽璟制药8月7日盘中最高价报122.0元。本周关注点来自业绩披露要点：公司自成立以来首次实现半年度盈利，归母净利润为64,001.11万元。机构调研要点2026年上半年，公司实现营业收入120,537.96万元，同比增长220.88%，主要因确认技术授权收入66,230.95万元及商业化产品销售增长；归母净利润达64,001.11万元，首次实现半年度盈利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","688266","BK1574","01477","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656311586","title":"泽璟制药（688266）2026年中报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2656311586","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656311586?lang=zh_cn&edition=full","pubTime":"2026-08-02 06:01","pubTimestamp":1785621676,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泽璟制药发布2026年中报。截至本报告期末，公司营业总收入12.05亿元，同比上升220.88%，归母净利润6.4亿元，同比上升979.09%。本报告期泽璟制药盈利能力上升，毛利率同比增幅5.55%，净利率同比增幅363.94%。持有泽璟制药最多的基金为汇添富创新医药混合A，目前规模为89.62亿元，最新净值1.6913，较上一交易日上涨0.21%，近一年下跌15.46%。本文数据来源于泽璟制药2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200001246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","688266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656182573","title":"泽璟制药(688266)6月30日股东户数1.37万户，较上期增加64.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656182573","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656182573?lang=zh_cn&edition=full","pubTime":"2026-08-01 17:02","pubTimestamp":1785574924,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泽璟制药披露，截至2026年6月30日公司股东户数为1.37万户，较3月31日增加5354.0户，增幅为64.17%。在化学制药行业个股中，泽璟制药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年3月31日至2026年6月30日，泽璟制药区间涨幅为18.08%，在此期间股东户数增加5354.0户，增幅为64.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100012774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","01477","BK0239","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655039357","title":"泽璟制药(688266.SH)发布半年度业绩，归母净利润6.4亿元，同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2655039357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655039357?lang=zh_cn&edition=full","pubTime":"2026-07-31 18:28","pubTimestamp":1785493730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)披露2026年半年度报告，报告期公司实现营收12.05亿元，同比增长220.88%;归属于上市公司股东的净利润6.4亿元，同比扭亏为盈;扣非净利润6.17亿元，同比扭亏为盈;基本每股收益2.42元。营业收入大幅增长主要系公司报告期确认产品技术授权许可相关收入6.62亿元，同时商业化产品的销售收入与上年同期相比增长44.30%。归属于上市公司股东的净资产较上年同期增加59.24%，公司自成立以来首次实现半年度盈利，带动净资产相应增长。同时，扣除非经常性损益前后的每股收益、加权平均净资产收益率均由负转正。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653322764","title":"富国基金朱少醒旗下基金二季报出炉！中际旭创(300308.SZ)、泽璟制药(688266.SH)首度进入前十大重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653322764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653322764?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:08","pubTimestamp":1784621322,"startTime":"0","endTime":"0","summary":"截至二季度末，中际旭创、泽璟制药首度进入该基金的前十大重仓股，分别成为第六大、第七大重仓股。同时，中国平安、滨江集团再度进入该基金的前十大重仓股，徐工机械、紫金矿业、瑞丰新材、贵州茅台集体退出该基金的前十大重仓股。截至二季度末，该基金继续重仓持有宁波银行，并且持股数量与上个季度保持不变。截至2026年二季度末，该基金已连续24个季度重仓宁波银行，持仓市值达14.85亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470316.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0871576103.HKD","688266","LU0039217434.USD","LU1655091616.SGD","LU1770034418.SGD","LU1064131003.USD","LU1580142542.USD","LU0708995583.HKD","LU2008162690.USD","LU2778985437.USD","LU1064130708.USD","LU0082770016.SGD","SG9999011746.SGD","91530","300308","LU0469268626.HKD","01477","LU1251922891.USD","SGXZ49509284.SGD","BK0167","BK0070","LU0572944931.SGD","LU2476274720.SGD","LU1719994722.HKD","SGXZ81163826.USD","LU0348735423.USD","LU1720050803.USD","LU2148510915.USD","LU0164939612.USD","LU0210526637.USD","LU2495084118.USD","LU1781817850.SGD","LU1979443071.USD","IE0034224299.USD","LU1820825898.SGD","LU1303224171.USD","BK1191","LU0348827113.USD","LU0634319403.HKD","LU1997245177.USD","LU0231483743.USD","IE0032431581.USD","LU1961090484.USD","HK0000320223.HKD","LU0327786744.USD","LU1794554557.SGD","LU2399975544.HKD","LU2177674079.SGD","LU2476274308.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661537","title":"泽璟制药（688266）披露股票交易异常波动公告，7月3日股价上涨4.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661537","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648661537?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:04","pubTimestamp":1783087465,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，泽璟制药报收于143.0元，较前一交易日上涨4.91%，最新总市值为378.53亿元。该股当日开盘135.0元，最高146.02元，最低125.69元，成交额达19.35亿元，换手率为5.45%。近日，泽璟制药发布《股票交易异常波动公告》。公告显示，公司股票交易连续3个交易日内日收盘价格涨幅偏离值累计达到30%，构成股票交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1191","01477","688266"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793728321347,"stockEarnings":[{"period":"1week","weight":-0.1109},{"period":"1month","weight":-0.2402},{"period":"3month","weight":-0.2426},{"period":"6month","weight":-0.2002},{"period":"1year","weight":-0.2115},{"period":"ytd","weight":-0.0984}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0609},{"period":"3month","weight":-0.0697},{"period":"6month","weight":-0.1368},{"period":"1year","weight":-0.0926},{"period":"ytd","weight":-0.0909}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13807人(较上一季度增加0.80%)","perCapita":"19172股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、盐酸吉卡昔替尼片、重组人凝血酶、注射用人促甲状腺素β。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药-U,688266,泽璟制药-U股票,泽璟制药-U股票老虎,泽璟制药-U股票老虎国际,泽璟制药-U行情,泽璟制药-U股票行情,泽璟制药-U股价,泽璟制药-U股市,泽璟制药-U股票价格,泽璟制药-U股票交易,泽璟制药-U股票购买,泽璟制药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药-U(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药-U(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}